<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option: Additional efficacy endpoints from the TROPION-Breast02 study.

Simple item page
dc.contributor.authorCescon, David W.
dc.contributor.authorTraina, Tiffany A.
dc.contributor.authorSchmid, Peter
dc.contributor.authorCortes, Javier
dc.contributor.authorShao, Zhimin
dc.contributor.authorSaji, Shigehira
dc.contributor.authorJung, Kyung Hae
dc.contributor.authorBachelot, Thomas
dc.contributor.authorWang, Shouman
dc.contributor.authorRamirez, Emilio Murillo
dc.contributor.authorBasaran, Gul
dc.contributor.authorChae, Yee Soo
dc.contributor.authorStradella, Agostina
dc.contributor.authorMathiba, Rofhiwa
dc.contributor.authorChen, Shin-Cheh
dc.contributor.authorBattelli, Nicola
dc.contributor.authorNiikura, Naoki
dc.contributor.authorZhao, Kechen
dc.contributor.authorMaxwell, Micah J.
dc.contributor.authorDent, Rebecca Alexandra
dc.date.accessioned2026-11-05T11:08:53Z
dc.date.issued2026
dc.description.issue16_SUPPL
dc.description.pages1002
dc.description.sponsorshipThis trial is sponsored by AstraZeneca. In July 2020, Daiichi Sankyo entered into a global development and commercialisation collaboration with AstraZeneca for datopotamab deruxtecan (Dato-DXd).
dc.description.volume44
dc.identifier.doi10.1200/JCO.2026.44.16_suppl.1002
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.urihttps://doi.org/10.1200/JCO.2026.44.16_suppl.1002
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/11582
dc.identifier.wosWOS:001780554000050
dc.language.isoen
dc.publisherLIPPINCOTT WILLIAMS & WILKINS
dc.relation.conferenceAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
dc.relation.fundingThis trial is sponsored by AstraZeneca. In July 2020, Daiichi Sankyo entered into a global development and commercialisation collaboration with AstraZeneca for datopotamab deruxtecan (Dato-DXd).
dc.relation.hasversion10.1200/JCO.2026.44.16_suppl.1002
dc.relation.ispartofJOURNAL OF CLINICAL ONCOLOGY
dc.subjectOncology
dc.titleFirst-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option: Additional efficacy endpoints from the TROPION-Breast02 study.
dc.typeMeeting Abstract
oaire.citation.editionScience Citation Index Expanded (SCI-EXPANDED)
oaire.citation.editionConference Proceedings Citation Index - Science (CPCI-S)
oaire.citation.issue16_SUPPL
oaire.citation.volume44
person.identifier.orcid0000-0001-9817-5228
person.identifier.ridMFH-6808-2025

Files

Collections

WOS